News

An NHS trust has agreed a three-year plan to cut up to £260m from its budget and break even. Under the plan, NHS Shropshire, ...
Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...
Key health updates involve Brazil's bird flu trade restrictions, Nestle USA's removal of synthetic food colors, Walgreens ...
An international probe reveals that several India-made chemotherapy drugs failed quality tests, risking lives across 100+ ...
AI trade rebounds as Nvidia leads generative AI surge. Explore key market moves, tech earnings insights, and ETF performance.
India is entering a new era of medical weight loss with the introduction of powerful drugs like Wegovy, and the growing off-label use of Ozempic and ...
Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...
Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a ...
Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a fast-growing market.
With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...
India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...